AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05493787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality
Study NCT05493787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patient portal, SMS, email, and/or another modality
Study NCT06635681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined chemotherapy
Description: Induction therapy(1 cycle):~Daunorubicin 60mg/m2/d d1-3 Cytarabine 100mg/m2/d d1-7 Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7 If the first course of treatment did not result in CR, patients with therapeutic target could be treated with targeted drugs, and the patients without targets would be treated with HAV regimen: Cytarabine 100mg/m2/d, d1-5, Homoharringtonine 2mg/m2 d1-5, Venetoclax 100mg d-2, 200mg d-1, 400mg d1-7.~Consolidation therapy(3 cycles):~Cytarabine 2g/m2 q12h d1-3 Venetoclax 400mg d1-7 For patients with CBF and CEBPA dual mutations, the dose of cytarabine is 3g/m2.~Maintenance treatment(6 cycles):~Azacitidine 75mg/m2/d d1-5 Venetoclax 400mg d1-7~Allogeneic hematopoietic stem cell transplantation is recommended for high-risk groups and intermediate-risk with positive measurable residual disease.
Study NCT04260230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifetemp/Lifetouch sensors
Description: Wearing the devices for six weeks. Data only reviewed retrospectively.
Study NCT06556433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Rewards
Description: Participants in the Rewards Group will have abstinence reinforced through escalating financial incentives.
Study NCT05361577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoplulse Mollii suit
Description: Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
Study NCT05361577 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exopulse Mollii suit (sham)
Description: In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
Study NCT05617157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stair stepping
Description: stepping up and down 32 stairs for 1 minute
Study NCT04906993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab； famitinib malate
Description: Camrelizumab intravenously ; Famitinib Orally
Study NCT04906993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based chemotherapy
Description: Physician's choice chemotherapy
Study NCT06286137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music for 1 minute
Description: Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 19 minutes before the 1 minute music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
Study NCT06286137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music for 5 minutes
Description: Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 1 minute through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels. The 15 minutes before the 5 minutes music listening intervention, participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones).
Study NCT06286137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music for 20 minutes
Description: Participants will be instructed to make a 20-minute playlist with their own preferred music, using a tablet and a music listening app. That playlist will then be presented on shuffle mode for 20 minutes through headphones provided by the hospital. Volume can be selected by the participants. However, in order to prevent hearing loss the volume cannot exceed 80 decibels.
Study NCT06286137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Not listening to music
Description: Participants will be instructed to remain seated and are not allowed to do anything else (for example using their phones), for a duration of 20 minutes.
Study NCT05145569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin AUC 5 and paclitaxel
Description: Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
Study NCT05145569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 and paclitaxel
Description: Carboplatin AUC 5 and paclitaxel combination chemotherapy is very well tolerated and highly effective for the treatment of ovarian cancer and thus is standard of care therapy. Both carboplatin and paclitaxel are chemotherapy agents that are designed to kill and slow the growth of cancer cells.
Study NCT05145569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCW9218
Description: HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
Study NCT05656664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid supplementation to assess for increased arsenic metabolite excretion
Study NCT05656664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group to assess arsenic metabolite excretion
Study NCT04535401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04535401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04535401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging
Study NCT05508048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The existential approach and logotherapy-based psychosocial support program
Description: Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
Study NCT05817149 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples
Study NCT04535401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO
Study NCT04535401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04535401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT04535401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT05801029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
Study NCT05801029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
Study NCT05924789 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study NCT05569252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1211b
Description: DS-1211b tablet administered once daily in the morning either in the fasted state or with a meal
Study NCT05569252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered once daily in the morning either in the fasted state or with a meal
Study NCT05302921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation Therapy
Description: Cryoablation therapy is an established method of cancer treatment in adults and pediatrics with certain types of tumors and is standard of care for certain tumors in the setting of progression/relapse.~Percutaneous image-guided Cryoablation (cryosurgery, cryotherapy) is a technique that utilizes successive rapid freeze/thaw cycles to destroy tumor cells. This technique is performed by inserting specialized needles known as cryoprobes into target tumors under imaging guidance with Computed Tomography (CT) and Ultrasound (US), or Magnetic Resonance Imaging (MRI). After the cryoprobe needles are placed within the target tumor, rapid cooling of liquid gas inserted into these probes leads to temperatures reaching -20 to -40 degrees Celsius.~Cryoablation therapy of one disease site will be done starting Day 3 and prior to Day 15 of Cycle 1 only.
Study NCT05302921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (Bristol Myers Squibb) is a human monoclonal antibody (immunoglobulin G4) that targets the programmed death-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease.
Study NCT05302921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (Bristol Myers Squibb) is a fully human monoclonal immunoglobulin G1Κ specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4, cluster of differentiation \[CD\]152), which is expressed on a subset of activated T-cells.~Nivolumab and ipilimumab will be given on day 1 of 21-day cycles for cycles 1-4, followed by nivolumab alone on days 1 and 15 of 28-day cycles for cycles 5+. Patients will receive up to 13 cycles of therapy unless unacceptable toxicity or progression of disease.
Study NCT06639724 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
Description: Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
Study NCT06156163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation training
Description: The exercise program will be applied 2 days/week for 8 weeks, with the addition of progressive perturbation conditions.
Study NCT06156163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise program will be applied 2 days/week for 8 weeks.
Study NCT04795466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Biological sub-cutaneous injection
Study NCT04795466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo subcutaneous injection
Study NCT06266806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources
Description: Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
Study NCT06254313 — intervention group
Intervention type: OTHER
Intervention: Additional tubes and LBA
Description: 4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)
Study NCT05871905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591
Description: C14 TY-9591
Study NCT06468280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local treatment (Surgical)
Description: Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.
Study NCT06468280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
Study NCT06468280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 Monoclonal Antibody
Description: PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
Study NCT06468280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX Chemotherapy Regimen
Description: Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle.
Study NCT06468280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX Chemotherapy Regimen
Description: Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle.
Study NCT06468280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Treatment (Non-surgical)
Description: Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team.
Study NCT06087536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMN6
Description: Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
Study NCT06087536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
Study NCT06137963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transform10 Diabetes Prevention Program
Description: The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation.
Study NCT06137963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transform10 Diabetes Prevention Program
Description: The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation.
Study NCT04939272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level.
Study NCT04939272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
Study NCT06212414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Programme
Description: Intervention based on Acceptance and Commitment Therapy, mindfulness, and compassion approaches
Study NCT06212414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: This intervention promotes the sharing of cancer-related experiences, active listening, and a sense of community between participants
Study NCT05151926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full weight-bearing
Description: Instruction for full and immediate weight-bearing postoperatively
Study NCT05151926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial weight-bearing
Description: Instruction for partial weight-bearing for 6 weeks postoperatively
Study NCT05151926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Description: Intramedullary nailing of the fractured tibial shaft.
Study NCT05151926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nailing
Description: Intramedullary nailing of the fractured tibial shaft.
Study NCT04933552 — intervention group
Intervention type: OTHER
Intervention: Siponimod
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
Study NCT05275725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
Study NCT05898711 — intervention group
Intervention type: DEVICE
Intervention: Fish skin graft
Description: Kerecis Fish Skin Graft - SurgiBind